{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:59:55Z","timestamp":1790449195978,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaccas.2026.108672","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:27:57Z","timestamp":1780486077000},"page":"108672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triple M Overlap Syndrome After Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"31","author":[{"given":"Maria F.","family":"Osorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekhya","family":"Mitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabricio","family":"Malaguez-Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay T.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Bilusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Wever-Pinzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis S.","family":"Chatzizisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2026.108672_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jaccas.2026.108672_bib2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor\u2013induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.jaccas.2026.108672_bib3","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.jaccas.2026.108672_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","article-title":"Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction","volume":"7","author":"Chen","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"12","key":"10.1016\/j.jaccas.2026.108672_bib5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.jaccas.2026.108672_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.jaccas.2026.108672_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.jaccas.2026.108672_bib8","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jaccas.2026.108672_bib9","article-title":"Myocarditis, myositis, and myasthenia gravis: the complexities of treating steroid-refractory triple M syndrome","volume":"30","author":"Halloran","year":"2025","journal-title":"JACC Case Rep"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926018310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926018310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:59:10Z","timestamp":1785959950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926018310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666084926018310"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108672","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple M Overlap Syndrome After Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"108672"}}